Analysts’ Viewpoint on Biobanking Market Scenario
Biobanking represents a new and innovative research field that involves international infrastructure and governmental organizations, which help in the adoption of best practices and provide scientific, ethical, and legal guidelines for the industry and public health. Imaging biobanks connected to biological samples and patients' clinical data is a new area in biobanking. Biobanks can help create multi-omics biobanks, where findings from genomics, proteomics, and metabolomics could be combined with radiomic data to create a novel and individualized method of treating a disease. Biobanking is becoming more sophisticated, akin to any industry in its early stages of development. Automation will play a significant role in biobanking storage, as the movement toward centralization and standardization continues. The global biobanking market size is expected to be driven by the growth in demand for personalized medicine, which will broaden the applications of biospecimen to facilitate ground-breaking treatments in areas of complex disease in the next few years.
The term 'biobanking' is often misused to refer to any collection of human biological specimens (biospecimens), regardless of the standards established for various tissue collection procedures or requirements pertaining to ethical and legal considerations. The process of collecting bodily fluids or tissue samples for usage in research to better understand health and disease is referred to as biobanking. Biobank is a sizable collection of biospecimens that are kept primarily for usage in health and medical research, and are linked to pertinent personal and health data (such as electronic medical record, family history, lifestyle, and genetic information).
The National Centre for Advanced Research and Excellence in Heart Failure (CARE-HF) at SCTIMST was established by ICMR to expand research in the field, as heart failure emerged as a significant health issue in India. One of the project's key components is the Heart Failure Biobank, which received funding of US$ 85,000 to build cutting-edge storage facilities.
In terms of usage and design (focused on populations or diseases), biobanks are diverse (epidemiology, translational, pharmaceutical research). Biobanks include information and samples from large-scale epidemiologic collections, family studies, patients with a particular disease, clinical trials of novel treatments, or patients with the disease in question. Data and samples are invariably gathered according to various guidelines, standards, and objectives.
According to the biobanking market analysis, little standardization has taken place across biobanks due to the challenges of data collection and sample storage within studies. The field of biome biobank research is rapidly evolving; however, the necessary biobanking infrastructure is currently fragmented and unprepared for microbiome biobanking. A number of international initiatives and protocols have recently been developed to address this issue. The goal of procedure standardization and harmonization is to facilitate data sharing among various resources, increasing effective sample size and statistical power, particularly for rare diseases.
Request a sample to get extensive insights into the Biobanking Market
Diversity of public participation in biobanking is a highlight of biobank success. Increase in number of biobanks across the world reflects their potential to improve the reproducibility and meaning of data generated by biomedical research. The fact that biospecimens are collected using strict and standardized methodologies ensures reproducibility, while meaningfulness is achieved by linking relevant information to biospecimens themselves as well as their donors. Biobanks' success is dependent on the participation of diverse groups of people.
Increase in funding for biobanking from private and government organizations and expansion of application areas of bio-banked samples are the major factors driving the global biobanking market size. Availability of government funding for regenerative medicine, stem cell therapeutics, and cell & gene therapy is encouraging research in this area. Furthermore, growth in trend of cord blood banking is expected to contribute to the growth of the market.
Future prospects, such as advancements in orthopedic procedures using stem cells, are expected to fuel the regenerative medicine market. Genomic research is a key driver of the global market. Government support for regenerative medicine research through various initiatives is also likely to increase biobanking market share.
Based on product, the equipment segment accounted for the largest share of the global biobanking market in 2021. Biobanking equipment is used in biorepositories to store biological samples for research purposes. Researchers use biobanking equipment to conduct tests or analyze specimens stored in a biobank. Along with equipment and consumables, software and services play an important role in assisting researchers in their studies of various diseases.
Surge in demand for personalized medicine, owing to high unmet medical requirements for developing effective therapies, is a key factor propelling the equipment segment. Increase in pharmaceutical R&D budgets by governments and private players is expected to support research activities. This is likely to augment the equipment segment.
Request a custom report on Biobanking Market
In terms of biospecimen type, the blood products segment held significant market share in 2021. Blood is one of the most frequently used biospecimens in research. Depending on the downstream application and blood fraction required, it is collected in tubes containing preservatives and additives (serum, plasma, white blood cells, red cells). Serum samples are typically collected in tubes containing a clot accelerator such as thrombin or silica, while plasma samples can be collected in tubes containing various anticoagulant additives. Majority of biochemical analyses are performed on serum, while DNA and RNA analyses are performed on anticoagulated blood. These practices have the potential to introduce heterogeneity into basic data. Citrate-stabilized blood, for example, yields higher DNA and RNA quality and more lymphocytes for culture than other anti-coagulants, while EDTA-coated collection tubes would be preferred for protein assays and most DNA-molecule analyses.
Based on application, the therapeutics segment is projected to account for major share of the global biobanking market during the forecast period. Clinical trials and research-based innovative activities such as personalized medicine aim to broaden the applications of biospecimens in research. Demand for precision medicines is high, as these promise breakthrough treatments in the most complex disease areas. Biobanks stand to benefit significantly from the growth in trend of precision medicines due to the sample data they possess, which is critical to precision medicine applications in therapy areas such as oncology, psychiatry, infectious diseases, and cardiology.
Institutes are conducting studies on the usage of cord blood in various areas of science that could benefit human health. The Lund University in Sweden launched the world's largest biobank in 2020 to better understand and conduct research in the most common diseases such as Alzheimer's, Parkinson's, cardiovascular disease, and diabetes. Hence, surge in research activities has been observed in cord blood applications in the past few years. This is expected to increase the demand for cord blood, which in turn, is likely to augment the therapeutics segment.
In terms of storage type, the automated segment is anticipated to grow at a rapid pace during the forecast period. Increase in demand for biobanking has induced biobanks to turn to automation to help maintain sample integrity and uphold their stringent specimen tracking standards. Automation can be used to improve access, cost, and throughput at various stages of the biobanking process.
Automated transport of biological samples from clinics and pre-analytical labs to the biobank has several advantages over manual sample transport. The primary advantage is the ability to deliver specimens 24 hours a day, seven days a week, without the need for staff to be present at all times, resulting in lower personnel costs. Moving samples around the lab can be aided by automated workstations.
In order to ensure consistent quality, the collection, processing, storage, and retrieval of samples by biobanks and biorepositories should be standardized, harmonized, and quality controlled to the highest level possible. This can be accomplished by putting in place a quality management system (QMS) and standard operating procedures (SOPs). Implementing technical solutions, particularly the automation of critical biobanking process areas, could help support this process. Automation improves reproducibility and accuracy, while decreasing the incidence of mislabeled or misplaced samples by reducing or eliminating human handling steps.
North America accounted for the largest share of the global biobanking market in 2021. The region is projected to be a highly lucrative market during the forecast period, with high market attractiveness index. This can be ascribed to the increase in adoption of advanced technologies and rise in awareness about biobanking among healthcare professionals and individuals working in the research and development industry. Furthermore, increase in R&D activities in the healthcare sector to develop novel biobanking and presence of major players are anticipated to drive the biobanking market in the region during the forecast period.
The market in Asia Pacific is expected to grow at a rapid pace from 2022 to 2031. This can be ascribed to the increase in geriatric population, which is more susceptible to chronic diseases; better health care infrastructure; and rise in demand for biospecimen products in the region.
The global biobanking market is consolidated, with the presence of small number of leading players. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the leading players in the global biobanking market. Thermo Fisher Scientific, Inc., PHC Holdings Corporation (Panasonic Healthcare), Hamilton Company, Chart Industries, Inc., VWR International, LLC, QIAGEN N.V., Greiner AG, Brooks Automation, Inc., Merck KGaA, and Tecan Trading AG are the prominent players operating in the global biobanking market.
Each of these players has been profiled in the biobanking market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
| Attribute | Detail |
|---|---|
| Market Size Value in 2021 | US$ 50.1 Bn |
| Market Forecast Value in 2031 | More than US$ 87.4 Bn |
| Growth Rate (CAGR) | 5.9% |
| Forecast Period | 2022-2031 |
| Historical Data Available for | 2017-2020 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
The global biobanking market was valued at US$ 50.1 Bn in 2021
The global market is projected to reach more than US$ 87.4 Bn by 2031
The global biobanking market is anticipated to grow at a CAGR of 5.9% from 2022 to 2031
Advancements in biobanking and growth in trend of conserving cord blood stem cells of newborns are driving the global biobanking market
North America is expected to account for major share of the global biobanking market during the forecast period
Thermo Fisher Scientific, Inc., Tecan Group Ltd., Qiagen N.V., Hamilton Company, Brooks Automation, TTP Labtech Ltd., VWR Corporation, Promega Corporation, Worthington Industries, Chart Industries, Becton, Dickinson and Company, and Merck KGaA
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Biobanking Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Biobanking Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Technological Advancement
5.2. List of Major Biobanks, by Region
5.3. List of Vendors Supporting Automated Biobanking
5.4. COVID-19 Impact Analysis
5.5. Regulatory Scenario by Region/globally
6. Global Biobanking Market Analysis and Forecast, by Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product, 2017-2031
6.3.1. Equipment
6.3.1.1. Temperature Control Systems
6.3.1.2. Incubators & Centrifuges
6.3.1.3. Alarms & Monitoring Systems
6.3.1.4. Accessories & Other equipment
6.3.2. Consumables
6.3.2.1. Cryovials & Cryomolds
6.3.2.2. Tubes
6.3.2.3. Others
6.3.3. Software & Services
6.4. Market Attractiveness Analysis, by Product
7. Global Biobanking Market Analysis and Forecast, by Biospecimen Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Biospecimen Type, 2017-2031
7.3.1. Blood Products
7.3.2. Human Tissues
7.3.3. Cell Lines
7.3.4. Nucleic Acids
7.3.5. Others
7.4. Market Attractiveness Analysis, by Biospecimen Type
8. Global Biobanking Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Application, 2017-2031
8.3.1. Therapeutics
8.3.2. Clinical Diagnostics
8.3.3. Drug Discovery & Development
8.3.4. Others
8.3.5. Neuropathic Pain
8.3.6. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Biobanking Market Analysis and Forecast, by Storage Product
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Storage Product, 2017-2031
9.3.1. Manual
9.3.2. Automated
9.4. Market Attractiveness Analysis, by Storage Product
10. Global Biobanking Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness Analysis, by Region
11. North America Biobanking Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017-2031
11.2.1. Equipment
11.2.1.1. Temperature Control Systems
11.2.1.2. Incubators & Centrifuges
11.2.1.3. Alarms & Monitoring Systems
11.2.1.4. Accessories & Other equipment
11.2.2. Consumables
11.2.2.1. Cryovials & Cryomolds
11.2.2.2. Tubes
11.2.2.3. Others
11.2.3. Software & Services
11.3. Market Value Forecast, by Biospecimen Type, 2017-2031
11.3.1. Blood Products
11.3.2. Human Tissues
11.3.3. Cell Lines
11.3.4. Nucleic Acids
11.3.5. Others
11.4. Market Value Forecast, by Application, 2017-2031
11.4.1. Therapeutics
11.4.2. Clinical Diagnostics
11.4.3. Drug Discovery & Development
11.4.4. Others
11.4.5. Neuropathic Pain
11.4.6. Others
11.5. Market Value Forecast, by Storage Product, 2017-2031
11.5.1. Manual
11.5.2. Automated
11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Product
11.7.2. By Biospecimen Type
11.7.3. By Application
11.7.4. By Storage Product
11.7.5. By Country
12. Europe Biobanking Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017-2031
12.2.1. Equipment
12.2.1.1. Temperature Control Systems
12.2.1.2. Incubators & Centrifuges
12.2.1.3. Alarms & Monitoring Systems
12.2.1.4. Accessories & Other equipment
12.2.2. Consumables
12.2.2.1. Cryovials & Cryomolds
12.2.2.2. Tubes
12.2.2.3. Others
12.2.3. Software & Services
12.3. Market Value Forecast, by Biospecimen Type, 2017-2031
12.3.1. Blood Products
12.3.2. Human Tissues
12.3.3. Cell Lines
12.3.4. Nucleic Acids
12.3.5. Others
12.4. Market Value Forecast, by Application, 2017-2031
12.4.1. Therapeutics
12.4.2. Clinical Diagnostics
12.4.3. Drug Discovery & Development
12.4.4. Others
12.4.5. Neuropathic Pain
12.4.6. Others
12.5. Market Value Forecast, by Storage Product, 2017-2031
12.5.1. Manual
12.5.2. Automated
12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Product
12.7.2. By Biospecimen Type
12.7.3. By Application
12.7.4. By Storage Product
12.7.5. By Country/Sub-region
13. Asia Pacific Biobanking Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017-2031
13.2.1. Equipment
13.2.1.1. Temperature Control Systems
13.2.1.2. Incubators & Centrifuges
13.2.1.3. Alarms & Monitoring Systems
13.2.1.4. Accessories & Other equipment
13.2.2. Consumables
13.2.2.1. Cryovials & Cryomolds
13.2.2.2. Tubes
13.2.2.3. Others
13.2.3. Software & Services
13.3. Market Value Forecast, by Biospecimen Type, 2017-2031
13.3.1. Blood Products
13.3.2. Human Tissues
13.3.3. Cell Lines
13.3.4. Nucleic Acids
13.3.5. Others
13.4. Market Value Forecast, by Application, 2017-2031
13.4.1. Therapeutics
13.4.2. Clinical Diagnostics
13.4.3. Drug Discovery & Development
13.4.4. Others
13.4.5. Neuropathic Pain
13.4.6. Others
13.5. Market Value Forecast, by Storage Product, 2017-2031
13.5.1. Manual
13.5.2. Automated
13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Product
13.7.2. By Biospecimen Type
13.7.3. By Application
13.7.4. By Storage Product
13.7.5. By Country/Sub-region
14. Latin America Biobanking Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017-2031
14.2.1. Equipment
14.2.1.1. Temperature Control Systems
14.2.1.2. Incubators & Centrifuges
14.2.1.3. Alarms & Monitoring Systems
14.2.1.4. Accessories & Other equipment
14.2.2. Consumables
14.2.2.1. Cryovials & Cryomolds
14.2.2.2. Tubes
14.2.2.3. Others
14.2.3. Software & Services
14.3. Market Value Forecast, by Biospecimen Type, 2017-2031
14.3.1. Blood Products
14.3.2. Human Tissues
14.3.3. Cell Lines
14.3.4. Nucleic Acids
14.3.5. Others
14.4. Market Value Forecast, by Application, 2017-2031
14.4.1. Therapeutics
14.4.2. Clinical Diagnostics
14.4.3. Drug Discovery & Development
14.4.4. Others
14.4.5. Neuropathic Pain
14.4.6. Others
14.5. Market Value Forecast, by Storage Product, 2017-2031
14.5.1. Manual
14.5.2. Automated
14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Product
14.7.2. By Biospecimen Type
14.7.3. By Application
14.7.4. By Storage Product
14.7.5. By Country/Sub-region
15. Middle East & Africa Biobanking Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017-2031
15.2.1. Equipment
15.2.1.1. Temperature Control Systems
15.2.1.2. Incubators & Centrifuges
15.2.1.3. Alarms & Monitoring Systems
15.2.1.4. Accessories & Other equipment
15.2.2. Consumables
15.2.2.1. Cryovials & Cryomolds
15.2.2.2. Tubes
15.2.2.3. Others
15.2.3. Software & Services
15.3. Market Value Forecast, by Biospecimen Type, 2017-2031
15.3.1. Blood Products
15.3.2. Human Tissues
15.3.3. Cell Lines
15.3.4. Nucleic Acids
15.3.5. Others
15.4. Market Value Forecast, by Application, 2017-2031
15.4.1. Therapeutics
15.4.2. Clinical Diagnostics
15.4.3. Drug Discovery & Development
15.4.4. Others
15.4.5. Neuropathic Pain
15.4.6. Others
15.5. Market Value Forecast, by Storage Product, 2017-2031
15.5.1. Manual
15.5.2. Automated
15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Product
15.7.2. By Biospecimen Type
15.7.3. By Application
15.7.4. By Storage Product
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player - Competitive Matrix (by tier and size of companies)
16.2. Market Share Analysis, by Company (2021)
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific, Inc.
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. SWOT Analysis
16.3.1.4. Financial Overview
16.3.1.5. Strategic Overview
16.3.2. PHC Holdings Corporation (Panasonic Healthcare)
16.3.2.1. Company Overview
16.3.2.2. Product Portfolio
16.3.2.3. SWOT Analysis
16.3.2.4. Financial Overview
16.3.2.5. Strategic Overview
16.3.3. Hamilton Company
16.3.3.1. Company Overview
16.3.3.2. Product Portfolio
16.3.3.3. SWOT Analysis
16.3.3.4. Financial Overview
16.3.3.5. Strategic Overview
16.3.4. Chart Industries, Inc.
16.3.4.1. Company Overview
16.3.4.2. Product Portfolio
16.3.4.3. SWOT Analysis
16.3.4.4. Financial Overview
16.3.4.5. Strategic Overview
16.3.5. VWR International
16.3.5.1. Company Overview
16.3.5.2. Product Portfolio
16.3.5.3. SWOT Analysis
16.3.5.4. Financial Overview
16.3.5.5. Strategic Overview
16.3.6. LLC (Avantor, Inc.)
16.3.6.1. Company Overview
16.3.6.2. Product Portfolio
16.3.6.3. SWOT Analysis
16.3.6.4. Financial Overview
16.3.6.5. Strategic Overview
16.3.7. QIAGEN N.V.
16.3.7.1. Company Overview
16.3.7.2. Product Portfolio
16.3.7.3. SWOT Analysis
16.3.7.4. Financial Overview
16.3.7.5. Strategic Overview
16.3.8. Greiner AG
16.3.8.1. Company Overview
16.3.8.2. Product Portfolio
16.3.8.3. SWOT Analysis
16.3.8.4. Financial Overview
16.3.8.5. Strategic Overview
16.3.9. Brooks Automation, Inc.
16.3.9.1. Company Overview
16.3.9.2. Product Portfolio
16.3.9.3. SWOT Analysis
16.3.9.4. Financial Overview
16.3.9.5. Strategic Overview
16.3.10. Merck KGaA
16.3.10.1. Company Overview
16.3.10.2. Product Portfolio
16.3.10.3. SWOT Analysis
16.3.10.4. Financial Overview
16.3.10.5. Strategic Overview
16.3.11. Tecan Trading AG.
16.3.11.1. Company Overview
16.3.11.2. Product Portfolio
16.3.11.3. SWOT Analysis
16.3.11.4. Financial Overview
16.3.11.5. Strategic Overview
16.3.12. Micronic
16.3.12.1. Company Overview
16.3.12.2. Product Portfolio
16.3.12.3. SWOT Analysis
16.3.12.4. Financial Overview
16.3.12.5. Strategic Overview
16.3.13. Greiner Bio One
16.3.13.1. Company Overview
16.3.13.2. Product Portfolio
16.3.13.3. SWOT Analysis
16.3.13.4. Financial Overview
16.3.13.5. Strategic Overview
16.3.14. Biobank AS
16.3.14.1. Company Overview
16.3.14.2. Product Portfolio
16.3.14.3. SWOT Analysis
16.3.14.4. Financial Overview
16.3.14.5. Strategic Overview
16.3.15. Biokryo GmbH
16.3.15.1. Company Overview
16.3.15.2. Product Portfolio
16.3.15.3. SWOT Analysis
16.3.15.4. Financial Overview
16.3.15.5. Strategic Overview
List of Tables
Table 01: Global Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 02: Global Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 03: Global Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 04: Global Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
Table 05: Global Biobanking Market Size (US$ Mn) Forecast, by Region, 2017-2031
Table 06: North America Biobanking Market Size (US$ Mn) Forecast, by Country, 2017-2031
Table 07: North America Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 08: North America Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 09: North America Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 10: North America Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
Table 11: Europe Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 12: Europe Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 13: Europe Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 14: Europe Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 15: Europe Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
Table 16: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 17: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 18: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 19: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 20: Asia Pacific Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
Table 21: Latin America Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 22: Latin America Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 23: Latin America Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 24: Latin America Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 25: Latin America Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
Table 26: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 27: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Product, 2017-2031
Table 28: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Application, 2017-2031
Table 29: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Biospecimen Type, 2017-2031
Table 30: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast, by Storage Type, 2017-2031
List of Figures
Figure 01: Global Biobanking Market Size (US$ Mn) and Distribution (%), by Region, 2021 and 2031
Figure 02: Global Biobanking Market Revenue (US$ Mn), by Product, 2021
Figure 03: Global Biobanking Market Value Share, by Product, 2021
Figure 04: Global Biobanking Market Value Share, by Application, 2021
Figure 05: Global Biobanking Market Value Share, by Biospecimen Type, 2021
Figure 06: Global Biobanking Market Value Share, by Storage Type, 2021
Figure 07: Global Biobanking Market Value Share, by Region, 2021
Figure 08: Global Biobanking Market Value (US$ Mn) Forecast, 2017-2031
Figure 09: Global Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 10: Global Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 11: Global Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 12: Global Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 13: Global Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031
Figure 14: Global Biobanking Market Attractiveness Analysis, by Storage type, 2022-2031
Figure 15: Global Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031
Figure 16: Global Biobanking Market Value Share Analysis, by Region, 2017 and 2031
Figure 17: Global Biobanking Market Attractiveness Analysis, by Region, 2022-2031
Figure 18: North America Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 19: North America Biobanking Market Attractiveness Analysis, by Country, 2017-2031
Figure 20: North America Biobanking Market Value Share Analysis, by Country, 2017 and 2031
Figure 21: North America Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 22: North America Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 23: North America Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031
Figure 24: North America Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031
Figure 25: North America Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 26: North America Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 27: North America Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022-2031
Figure 28: North America Biobanking Market Attractiveness Analysis, by Storage Type, 2022-2031
Figure 29: Europe Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 30: Europe Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 31: Europe Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 32: Europe Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 33: Europe Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 34: Europe Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031
Figure 35: Europe Biobanking Market Value Share Analysis, by Storage Type, 2022-2031
Figure 36: Europe Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 37: Europe Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 38: Europe Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022-2031
Figure 39: Europe Biobanking Market Attractiveness Analysis, by Storage Type, 2022-2031
Figure 40: Asia Pacific Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 41: Asia Pacific Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 42: Asia Pacific Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 43: Asia Pacific Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 44: Asia Pacific Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 45: Asia Pacific Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031
Figure 46: Asia Pacific Biobanking Market Value Share Analysis, by Storage Type, 2022-2031
Figure 47: Asia Pacific Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 48: Asia Pacific Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 49: Asia Pacific Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022-2031
Figure 50: Asia Pacific Biobanking Market Attractiveness Analysis, by Storage Type, 2022-2031
Figure 51: Latin America Biobanking Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 52: Latin America Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 53: Latin America Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 54: Latin America Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 55: Latin America Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 56: Latin America Biobanking Market Value Share Analysis, by Biospecimen Type, 2017 and 2031
Figure 57: Latin America Biobanking Market Value Share Analysis, by Storage Type, 2022-2031
Figure 58: Latin America Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 59: Latin America Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 60: Latin America Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022-2031
Figure 61: Latin America Biobanking Market Attractiveness Analysis, by Storage Type, 2022-2031
Figure 62: Middle East & Africa Biobanking Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017-2031
Figure 63: Middle East & Africa Biobanking Market Attractiveness Analysis, by Country/Sub-region, 2017-2031
Figure 64: Middle East & Africa Biobanking Market Value Share Analysis, by Country/Sub-region, 2017 and 2031
Figure 65: Middle East & Africa Biobanking Market Value Share Analysis, by Product, 2017 and 2031
Figure 66: Middle East & Africa Biobanking Market Value Share Analysis, by Application, 2017 and 2031
Figure 67: Middle East & Africa Biobanking Market Value Share Analysis, by Storage Type, 2017 and 2031
Figure 68: Middle East & Africa Biobanking Market Attractiveness Analysis, by Product, 2022-2031
Figure 69: Middle East & Africa Biobanking Market Attractiveness Analysis, by Application, 2022-2031
Figure 70: Middle East & Africa Biobanking Market Attractiveness Analysis, by Biospecimen Type, 2022-2031
Figure 71: Middle East & Africa Biobanking Market Attractiveness Analysis, by Storage Type, 2022-2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Biobanking Market
